Managers / Q2 2019 · view latest →
KNOTT DAVID M
CIK 0000808722
Summary
Knott David M reported $237M in U.S.-listed holdings across 148 positions for Q2 2019.
Its largest position, LGND, represents 17.0% of the portfolio.
Compared with Q1 2019, the fund opened 12 new positions and exited 11.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 74.9% · $177M
- MLP · 8.5% · $20M
- Other · 7.7% · $18M
- Ltd Part · 5.6% · $13M
- REIT · 2.0% · $5M
- Other · 1.4% · $3M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2019 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| Fannie Mae 8.25 Series T | NEW | +85.0K | 85.0K | +$996,000 | $996,000 |
| DDDupont DE Nemours Inc. | NEW | +12.5K | 12.5K | +$942,000 | $942,000 |
| Freddie Mac 8.375 Series Z | NEW | +53.4K | 53.4K | +$662,000 | $662,000 |
| DOWDow Inc. | NEW | +12.5K | 12.5K | +$619,000 | $619,000 |
| CTVACorteva Inc. | NEW | +12.5K | 12.5K | +$371,000 | $371,000 |
| GILDGilead Sciences, Inc. | NEW | +3.5K | 3.5K | +$236,000 | $236,000 |
| Cidara Therapeutics, Inc. | NEW | +128.5K | 128.5K | +$216,000 | $216,000 |
| CymaBay Therapeutics, Inc. | NEW | +21.0K | 21.0K | +$150,000 | $150,000 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2019
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2021 | $275M | 197 | Nov 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $281M | 195 | Aug 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $234M | 166 | May 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $221M | 145 | Feb 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $170M | 135 | Nov 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $183M | 127 | Aug 12, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $158M | 156 | May 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $247M | 152 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $238M | 157 | Nov 12, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $237M | 148 | Aug 12, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $251M | 143 | May 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $213M | 133 | Feb 12, 2019 | 13F-HR | changes · EDGAR ↗ |
Other Included Managers
This filing reports holdings on behalf of 1 additional manager.
- DORSET MANAGEMENT CORP028-10281
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.